Editorial Board

Annals of Immunology and Immunotherapy

Home AII Editorial Board Cody P Coyne

Share this profile

LinkedIn Twitter / X

✓ Link copied!

Cody P Coyne

Cody P Coyne

Editorial Board Member
Mississippi State University USA Member since 2018

Biography

Cody Coyne is a professor of Molecular Pharmacology and Immunology in the Department of Basic Sciences within the College of Veterinary Medicine where he has established a research program devoted to the molecular design, synthesis and potency evaluation of pharmaceuticals. Current research investigations have been devoted to the design of molecular structure, organic chemistry reactions and multi-phase synthesis regimens for covalent immunopharmaceuticals with properties of selective "targeted" delivery and potent anti-neoplastic cytotoxicity. A native of Colorado, Coyne earned a DVM from Colorado State University in Fort Collins; completed a surgery internship, an internal medicine residency, and a PhD graduate degree (radiobiopharmacology design) at the University of California at Davis/Sacramento Medical Center, and attained board certification with diplomate status in the College of Veterinary Internal Medicine while at Kansas State University. Since arriving at Mississippi State University in 1993, he has received extramural funding from federal, research foundation, and pharmaceutical industry sources primarily for pharmacology-oriented research related to infectious and neoplastic disease states relevant to both man and domestic animal species. In 2000 a U.S. Patent was issued for research methods developed that optimize the isolation, growth and propagation of a unique cell population that has utility for the synthetic production of medicinal glycoproteins through the application of genetic cloning techniques, and as a biological reagent in the development of new vaccine preparations (represents the first CVM research patent). Since that time, numerous pharmacology intellectual properties have been conceived and are in the active stages of development which have lead to the filing of multiple invention disclosures and non-disclosure agreements arranged with domestic pharmaceutical companies. Research that is currently active has generated investigations devoted to the molecular design, organic chemical synthesis and potency evaluation of anti-cancer agents with properties of selective "targeted" delivery that have efficacy against chemotherapeutic-resistant human carcinomas. Parallel research investigations involve the molecular design and chemical synthesis of candidate chemo-therapeutics that have been approved for Phase II analysis by a major pharmaceutical company.

Research Interests

Molecular Biology Proteomics Analyses Neoplastic Conditions Biopharmaceutical Agents Pharmaceutical Molecular Design Molecular Oncology Proteomics Modification Of Gene Transcription Internal Medicine Molecular Pharmacology

Other Editorial Board Members

Submit Manuscript

Chat with us on WhatsApp

Welcome to Medwin Publishers. How can we help you today?